The Pharma Data

DECEMBER 11, 2020

The University of Oxford has regularly appeared in our updates since July 2020, as its team of researchers leads an ongoing clinical trial for the Covid-19 vaccine. As we follow individuals over the course of a year, we are repeatedly testing them for both virus and antibodies.”.

Antibody 52

Antibody Vaccination Vaccine Containment 52

XTalks

JANUARY 21, 2025

The liquid portion of the blood (serum or plasma) containing antibodies is separated and tested using the Liason Biotrin parvovirus B19 IgG plus test on a Liason XL analyzer. If parvovirus B19 antibodies are present, they bind to the chemicals and particular particles in the test, producing a light signal.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

Pharmaceutical Technology

SEPTEMBER 8, 2022

The information contained within the download document is designed for pharmaceutical executives, developers, research scientists and associates, regulatory solutions consultants, and any other individual involved in API biologics production in the pharmaceutical industry.

Gene 100

Gene Marketing Vaccination Vaccine 100

The Pharma Data

NOVEMBER 25, 2020

26, 2020 /PRNewswire/ — Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis. LUND, Sweden , Nov. About BioInvent. About Cantargia.

Antibody 52

Antibody Manufacturing Clinical Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 17, 2020

17, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly ‘s potential COVID-19 therapies. Lilly ‘s chief scientific officer and president of Lilly Research Laboratories.

Antibody 52

Antibody Manufacturing Production Sales 52

Roots Analysis

DECEMBER 11, 2022

Antibody drug conjugates (ADCs) are an upcoming class of targeted therapeutic agents that have garnered the attention of pharmaceutical companies, and academic / research institutions across the world. Antibody drug conjugates market is presently an established therapeutic concept with 11 approved products.

Antibody 40

Antibody Marketing Contract Manufacturing Drugs 40

Camargo

DECEMBER 13, 2021

Both the FDA’s Center for Drug Evaluation and Research (CDER) and its Center for Biologics Evaluation and Research (CBER) have regulatory responsibility for therapeutic biological products, which are subject to both the Federal Food, Drug and Cosmetic (FD & C) Act and the Public Health Service (PHS) Act.

Development 161

Development Production Immune Response Licensing 161

Pharmaceutical Technology

AUGUST 24, 2022

The global immunotherapy market, which includes CAR T-cell therapy, adoptive cell therapies, checkpoint inhibitors, monoclonal antibodies, and other immunotherapies, is expected to grow by 10.1% Quantifiable results: Researchers can obtain relative percentages and learn the absolute count and number of receptors in a cell.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

pharmaphorum

NOVEMBER 28, 2021

The three-year phase 2 trial will be carried out by researchers at Leeds University led by professor of clinical oncology and neuro-oncology Susan Short, and see if adding Sativex (nabiximols) to standard chemotherapy for recurrent glioblastoma can extend survival. Jazz acquired rights to Sativex when it completed its $7.2

Trials 136

Trials Drugs Clinical Trials Clinical Trials 136

Delveinsight

OCTOBER 1, 2021

This disease is associated with antibodies directed against the acetylcholine receptor, muscle-specific kinase (MUSK), lipoprotein-related protein 4 (LRP4), or agrin in the postsynaptic membrane at the neuromuscular junction. Prograf is available for oral administration in the form of capsules (tacrolimus capsules USP) containing 0.5

Marketing 85

Marketing Antibody Drugs Sales 85

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

XTalks

MARCH 29, 2021

According to a study by researchers at the National Institutes of Health (NIH), moderate caffeine intake could lead to small babies. The research found that even consumption of less than the recommended moderate amount of 200 mg of caffeine per day for adults, which is about two cups of coffee, posed an increased risk to the fetus.

Genotype 98

Genotype Allergies Hormones Research 98

The Pharma Data

AUGUST 15, 2021

Now, researchers reporting in ACS Central Science have immunized mice with nanoparticles that mimic SARS-CoV-2 by displaying multiple copies of the receptor binding domain (RBD) antigen, showing that the vaccine triggers robust antibody and T cell responses. Although the first vaccines to receive Emergency Use Authorization by the U.S.

Protein 52

Protein Vaccination Vaccine Antibody 52

pharmaphorum

SEPTEMBER 16, 2020

Head of “Living With”, Mariel Metcalfe, discusses the nature of severe asthma and severe eosinophilic asthma, and presents some key findings from recent patient research conducted in Europe, USA and Japan. Medical researchers have identified that there are different types of asthma, and they respond differently to treatment.

Doctor 105

Doctor Doctors Research Containment 105

pharmaphorum

OCTOBER 31, 2022

s Inmazeb (consisting of the monoclonal antibodies atoltivimab, maftivimab, and odesivimab-ebgn). Indeed, Regeneron believes that the success with Ebola could potentially have ushered in “a new era in which monoclonal antibodies could be used to fight viral diseases and global pandemics.”.

Production 52

Production FDA Approval Antibody Gene 52

The Pharma Data

OCTOBER 28, 2020

NASDAQ: REGN) today announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints. Regeneron Pharmaceuticals, Inc. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron.

Antibody 40

Antibody Trials Production Clinical Trials 40

The Pharma Data

DECEMBER 5, 2020

NASDAQ: REGN) today announced updated data for REGN5458, a BCMAxCD3 bispecific antibody, from the Phase 1 portion of a Phase 1/2 trial in patients with relapsed or refractory (R/R) multiple myeloma. These allow for the creation of bispecific antibodies that closely resemble natural human antibodies with no linkers or artificial sequences.

Antibody 40

Antibody Production Trials Medicine 40

XTalks

JANUARY 9, 2024

Events and activities to mark Thyroid Awareness Month include self-checks for thyroid abnormalities, encouraging friends and family to get tested and making donations to related research or treatment institutions. Blocking BAFF interaction : Belimumab, which is an anti-BAFF monoclonal antibody in a Phase II trial.

Hormones 105

Hormones Antibody Trials Production 105

The Pharma Data

DECEMBER 1, 2020

is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. About Innate Pharma: Innate Pharma S.A. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia.

Containment 52

Containment Antibody Production Engineer 52

The Pharma Data

SEPTEMBER 3, 2020

The data, published today in Nature Medicine , demonstrated that the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited an immune response as demonstrated by “neutralizing antibodies” and prevented severe clinical disease – including weight loss, pneumonia and mortality – in Syrian golden hamsters upon challenge.

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

The Pharma Data

JANUARY 10, 2021

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / January 11, 2021 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today that Jean-Paul Kress, M.D., In July 2020, the U.S.

Containment 52

Containment Clinical Development Antibody Development 52

The Pharma Data

JANUARY 4, 2021

IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody format. IPH6101/SAR443579 is a NKp46-based NK cell engager (NKCE) using Innate’s proprietary multispecific antibody format (Gauthier et al. MARSEILLE, France, Jan. MARSEILLE, France, Jan. Cell 2019 ).

Development 40

Development Antibody Drugs Containment 40

The Pharma Data

JUNE 25, 2021

protofibril antibody for the treatment of Alzheimer’s disease (AD). Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Lecanemab selectively binds to neutralize and eliminate soluble, toxic amyloid-beta (A?)

Antibody 40

Antibody Clinical Trials Clinical Trials Development 40

The Pharma Data

JANUARY 26, 2021

from the Scripps Research Translational Institute in La Jolla, California, conducted a systematic review to estimate the proportion of persons infected with SARS-CoV-2 who never develop symptoms. The researchers found that a median of 72.3 TUESDAY, Jan. 22 in the Annals of Internal Medicine. Oran and Eric J. Topol, M.D.,

Containment 52

Containment Antibody Medicine Research 52

The Pharma Data

OCTOBER 25, 2020

Company Confirms COVID-19 Antibody Home Test and Two Severity Triage Tests can be Submitted to U.S. SQI is accelerating the clinical development of its direct-to-consumer COVID-19 HOME Antibody Test, its COVID-19 RALI-dx Severity Triage Test and its COVID-19 RALI- fast Severity Triage Point-of-Care (POC) Test.

Development 52

Development Antibody Clinical Development FDA Approval 52

The Pharma Data

DECEMBER 2, 2020

This press release contains forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Containment 52

Containment DNA Sales Antibody 52

The Pharma Data

JANUARY 27, 2021

RIIB antibody BI-1206 in combination with rituximab (anti-CD20 monoclonal antibody) in patients with indolent relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). (Nasdaq: CASI), a U.S. Wei-Wu He , Ph.D., About BioInvent. The Company’s validated, proprietary F.I.R.S.T

Antibody 52

Antibody Containment Development Trials 52

The Pharma Data

OCTOBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT), today announced that the European Patent Office (EPO) has granted Patent # 3328401 , which covers VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat oncology conditions. TEL AVIV, Israel, Oct. About VBL Vascular Biogenics Ltd.,

Antibody 40

Antibody Gene Therapy Containment Clinical Trials 40

The Pharma Data

NOVEMBER 9, 2020

President of Research and Development, Novavax. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Roots Analysis

FEBRUARY 15, 2022

Over time, medical researchers have been able to further develop their understanding of the intricacies of ADC design and have also improved the development process of these complex pharmacological interventions. ADCs are engineered therapeutics comprised of monoclonal antibodies attached to potent cytotoxic payloads through chemical linkers.

Contract Manufacturing 52

Contract Manufacturing Manufacturing Marketing Containment 52

The Pharma Data

JANUARY 19, 2021

RIIB antibody, BI-1206, a novel monoclonal antibody that specifically targets the antibody “brakes” to help overcome resistance to rituximab. His research focus is all possible aspects of malignant lymphomas, aiming for the improvement of the quality of life and survival of these patients. LUND, Sweden , Jan.

Antibody 40

Antibody Clinical Trials Clinical Trials Licensing 40

The Pharma Data

JULY 27, 2021

Acquisition Complements Amgen’s Antibody Research Capabilities Across Therapeutic Areas Acquisition Includes a Portfolio of Early-Stage Oncology Assets, Including a Phase 1 Bispecific Antibody for Patients With Advanced Prostate Cancer. executive vice president of Research and Development at Amgen. billion in cash.

Production 52

Production Antibody Sales Development 52

The Pharma Data

JANUARY 20, 2021

The new brand and values launch come after a year of significant growth at Polpharma Biologics, it has brought its Utrecht research and development site, formerly Bioceros, and its Warsaw manufacturing site under the Polpharma Biologics brand, and significantly expanded its workforce by over 250 employees.

Branding 52

Branding Manufacturing Production Containment 52

The Pharma Data

APRIL 3, 2021

Since we embarked on this development program, and throughout the pandemic, we have learned much from our scientific research. The antibodies in the H-Ig come from the liquid portion of blood, or plasma, donated by healthy people who have recovered from COVID-19.

Clinical Trials 52

Clinical Trials Clinical Trials Medicine Trials 52

The Pharma Data

JANUARY 26, 2021

” Some researchers have raised a concern that people who have already been infected with COVID-19 could be reinfected with the Brazilian variant. It contains a set of mutations that may affect its ability to be recognized by immune system antibodies, according to the U.S. Centers for Disease Control and Prevention.

Containment 52

Containment Antibody Scientist Research 52

Pfizer

FEBRUARY 16, 2023

GCP is the international ethical and scientific quality standard for clinical trials that all clinical researchers need to follow. Pfizer Disclosure Notice The information contained in this release is as of February 17, 2023. These standards are designed to put participants’ interests first and ensure high scientific integrity.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

Pfizer

FEBRUARY 9, 2023

Pfizer Disclosure Notice The information contained in this release is as of February 10, 2023. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. For more information, please visit www.BioNTech.com. 2013;81(10):928-930.

Vaccination 75

Vaccination Vaccine Clinical Trials Clinical Trials 75